Skip to Main Content


Charles John Robbins III

Characterizing the molecular and histologic features of HER2-low breast cancer to improve cancer diagnostics for emerging anti-HER2 therapies: The current IHC strategy for determining HER2-low status is very discordant amongst pathologists and insufficient for predicting response to HER2-low therapies. I plan to explore the biology of HER2-low breast cancer with state-of-the-art digital spatial profiling technologies, machine learning based image analysis, and novel HER2 expression assays to quantitively define this subgroup.

Mentor: David Rimm